Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00932152 · ClinicalTrials.gov registry record · Phase 2
Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer
A Phase 2 study, sponsored by University of Pittsburgh.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00932152: Clinical Trial Phase 2 study, sponsored by University of Pittsburgh.
NCT00932152 is a Phase 2 study that was terminated before completion, run by University of Pittsburgh. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00932152, a Phase 2 study, was terminated before completion, sponsored by University of Pittsburgh.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This research study will test whether dual anti-estrogen therapy (anastrozole and fulvestrant) slows the time to when the cancer progresses.
Interventions
- DRUG Best supportive care
- DRUG Bevacizumab (Avastin)
- DRUG fulvestrant (Faslodex)
- DRUG anastrozole (Arimidex)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Why NCT00932152 stopped before completion
NCT00932152 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 4 interventions - of which Best supportive care is the first listed.
NCT00932152 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00932152 about?
NCT00932152 is a clinical study titled "Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer". This research study will test whether dual anti-estrogen therapy (anastrozole and fulvestrant) slows the time to when the cancer progresses.
What is the current status of trial NCT00932152?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2010-09. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00932152?
The interventions under investigation include: Best supportive care (DRUG), Bevacizumab (Avastin) (DRUG), fulvestrant (Faslodex) (DRUG), anastrozole (Arimidex) (DRUG).
Who is sponsoring clinical trial NCT00932152?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00932152's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia